HONG KONG – The findings of new study by Chinese researchers have led to the discovery of a new means of increasing the anticancer activity of the immune system’s killer T cells by modifying cholesterol metabolism, which could be used to complement other current cancer immunotherapies, such as immune checkpoint blockade. Read More

SHANGHAI – Canbridge Life Sciences Ltd., a privately held biopharma in Beijing, has in-licensed AV-203, a clinical-stage ErbB3 (HER3) inhibitory antibody candidate from Aveo Oncology Inc., of Cambridge, Mass. While the candidate has been tested in numerous tumor models, Canbridge will develop AV-203 in esophageal squamous cell cancer (ESCC), the most prevalent form of esophageal cancer especially in China where half of all new cases arise. Read More

TOKYO – A long-standing and wide divide between Japan’s academia and the country’s pharmaceutical industry is resulting in top-notch research being left behind in university labs and science journals. Patients, of course, have the most at stake in this disconnected environment. Read More

TOKYO – With a liberalized regulatory environment, Japan is rapidly emerging as a major player in regenerative medicine and is attracting more companies eager to explore the market. Read More

SHANGHAI – While perusing the list of China’s most promising biopharmaceutical companies, a surprising fact emerges: Many are not registered in China as purely domestic firms, but operate here as wholly foreign-owned enterprises under a Cayman Islands holding company. Cayman Islands is a well-known business-friendly tax haven. Read More